Exelixis submits cabozantinib NDA to FDA
Cabozantinib is a potent targeted therapy that inhibits MET, VEGFR2 and RET. As a part of the NDA filing, which is based on data from a Phase III
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).